Skip to main content
SpringerLink
Log in

Klinische Bewertung der Wirksamkeit von Nootropika

  • Chapter
Neuro-Psychopharmaka

Zusammenfassung

Da tier- und humanexperimentell ermittelte pharmakologische und biochemische Untersuchungsergebnisse lediglich Aussagen zur Wirkung der Nootropika zulassen, muß die Bewertung der Wirksamkeit ausschließlich nach klinischen Kriterien erfolgen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • American Psychiatric Association (1989) Diagnostisches und statistisches Manual psychischer Störungen DSM-III-R. Übersetzt nach der Revision des Diagnostic and Statistical Manual of Mental Disorders der American Psychiatric Association. Deutsche Bearbeitung und Einführung von Wittchen H-U, Sass H, Zaudig M, Koehler K. Beltz, Weinheim

    Google Scholar 

  • Bergener M, Reisberg B (eds) (1989) Diagnosis and treatment of senile dementia. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  • Brunner C, Spiegel R (1990) Eine Validierungsstudie mit der Nosger (Nurses’ Observation Scale for Geriatric Patients), einem neuen Beurteilungsinstrument für die Psychogeriatrie. Z Klin Psychol 19: 1–19

    Google Scholar 

  • Buschke H (1973) Selective reminding for analysis of memory and learning. J Verbal Learning verbal Behav 12: 543–550

    Article  Google Scholar 

  • Carlsson A (1987) Brain neurotransmitters in aging and dementia: similar changes across diagnostic dementia groups. Gerontology 33: 159–167

    Article  PubMed  CAS  Google Scholar 

  • Ciompi L, Kanowski S et al. (1986) Dokumentationssystem der Arbeitsgemeinschaft für Gerontopsychiatrie. In: Collegium Internationale Psychiatriae Scalarum (Hrsg) Internationale Skalen für Psychiatrie. Beltz, Weinheim

    Google Scholar 

  • Cips Collegium Internationale Psychiatriae Scalarium (Hrsg) (1986) Internationale Skalen für Psychiatrie. Beltz, Weinheim

    Google Scholar 

  • Clinical Global Impressions (CGI) (1970) In: Guy W, Bonato RR (eds) Manual for the ECDEU assessment battery, 2nd revised ed. Chevy Chase, Maryland 1: 12–1–12–6

    Google Scholar 

  • Copeland JRM, Kelleher MJ, Kellett JM, Gourlay AJ, Gurland BJ, Fleiss JL, Sharp L (1976) A semistructured clinical interview for assessment of diagnosis and mental state in the elderly. The geriatric mental state schedule. I. Development and reliability. Psychol Med 6: 439–449

    Article  PubMed  CAS  Google Scholar 

  • Copeiand JRM, Mcwilliam C, Dewey ME, Forshaw D, Shiwach R, Abed R, Muthu MS, Wood N (1986) The early recognition of dementia in the elderly: a preliminary communication about a longitudinal study using the Gmsagecat package (community version). Int J Geriatr Psychol 1: 63–70

    Article  Google Scholar 

  • Coper H, Herrmann WM (1988) Psychostimulants, analgetics, nootropics: an attempt to differentiate and assess drugs designed for the treatment of impaired brain functions. Pharmacopsychiatry 21: 211–217

    Article  PubMed  CAS  Google Scholar 

  • Das Amdp-System (1981) Manual zur Dokumentation psychiatrischer Befunde, 4. Aufl. Springer, Berlin Heidelberg New York

    Google Scholar 

  • Crook T, Larrabee GJ (1988) Age-associated memory impairment. Diagnostic and therapeutic strategies. Psychopharmacol Bull 24: 509–514

    PubMed  CAS  Google Scholar 

  • Empfehlungen zum Wirksamkeitsnachweis von Nootropika im Indikationsnachweis “Demenz” (Phase III) (1991) Gemeinsames Papier der das Bundesgesundheitsamt beratenden Zulassungskommission für neue Stoffe (Kornmission A) und der Aufbereitungskommission “Neurologie, Psychiatrie” (Kommission B). Bunclesgesundheitsblatt 7: 342–350

    Google Scholar 

  • Erzigkeit H (1986) Syndrom-Kurz-Test, 2. überarbeitete Aufl. Vless, Ebersberg

    Google Scholar 

  • Ferris SH, Crook T, Clark E, Mccarthy M, Rae D (1980) Facial recognition memory deficits in normal aging and senile dementia. J Gerontol 35: 707–714

    Article  PubMed  CAS  Google Scholar 

  • Fletcher JC, Dommel FW JR, Cowell DD (1985) Consent to research with impaired human subjects. IRB. Rev. Hum Subject Res 7: 1–6

    Google Scholar 

  • Folstein MF, Folstein SE, Mchugh PR (1975) MiniMental-State. A practical method for grading the cognitive state of patients for the clinican. J Psychiatr Res 12: 189–198

    Article  PubMed  CAS  Google Scholar 

  • Fröstl W, Maître L (1989) The families of cognition enhancers. Pharmacopsychiatry 22: 54– 100

    Article  PubMed  Google Scholar 

  • Giotti A (ed) (1986) Drugs affecting cognitive disorders. Clin Neuropharmacol 9 [Suppl] 1–84

    Article  Google Scholar 

  • Gottfries CG, Braine G, Steen G (1982) A new rating scale for dementia syndromes. Gerontology 28 [Suppl 2]: 20–31

    Article  PubMed  Google Scholar 

  • Giurgea CE (1972) Vers une pharmacologie de l’activitè integrative au cerveau. Tentative du concept nootrope en psychopharmacologie. Actual Pharmacol 25: 115–157

    CAS  Google Scholar 

  • Giurgea CE (1979) Nootropic and related drugs interacting with the integrative activity of the brain. Dev Psychiatry 2: 876–881

    Google Scholar 

  • Giurgea CE (1982) The nootropic concept and its prospective implications. Drug Dev Res 2: 441–446

    Article  Google Scholar 

  • Gutzmann H, Kanowski S, Krüger H, Urban R, Ciompi L (1989) Das AGP-System. Manual zur Dokumentation gerontopsychiatrischer Befunde. Springer, Berlin Heidelberg New York Tokyo

    Book  Google Scholar 

  • Häfner H (1986) Psychische Gesundheit im Alter. G Fischer, Stuttgart New York

    Google Scholar 

  • Heiss WD, Beil C, Herholz K, Pawlik G, Wagner R, Wienhard K (1983) Atlas der Positronen-Emissions-Tomographie des Gehirns. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  • Helmchen H (1986) Ethische Fragen der Psychiatrie. In: Kisker KP, Lauter H, MEYER JE, Müller C, Strömgren E (Hrsg) Psychiatrie der Gegenwart, Bd 2. Krisenintervention, Suizid. Konsiliarpsychiatrie. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  • Helmchen H, Kanowski S, Koch H-G (1989) Forschung mit dementen Kranken. Forschungsbedarf und Einwilligungsproblematik. Ethik in der Medizin 1: 83–98

    Google Scholar 

  • Helmes E (1988) Multidimensional observation scale elderly subjects (MOSES). Psychopharmacol Bull 24: 733–745

    PubMed  CAS  Google Scholar 

  • Hock FJ (1987) Drug influence on learning and memory in aged animals and humans. Neuropsychobiology 17: 145–160

    Article  PubMed  CAS  Google Scholar 

  • Kam P Van Der, Mol F, Wimmers MFHG (1971) Beoordelingsschool voor Oudere Patienten. Van Loghum Slaterus, Niederlande

    Google Scholar 

  • Keim KL, Kiss B (eds) New drug strategies in the treatment of senile dementia of different origin. Drug Dev Res 14: 181–384

    Google Scholar 

  • Larrabee GJ, Crook T (1988) A computerized everyday memory battery for assessing treatment effects. Psychopharmacol Bull 24: 695–697

    PubMed  CAS  Google Scholar 

  • Lauter H, Möller HJ, Zimmer R (1986) Untersuchungs- und Behandlungsverfahren in der Gerontopsychiatrie. Springer, Berlin Heidelberg New York Tokyo

    Book  Google Scholar 

  • Lawton MG, Brody EM (1969) Assessment of older people. Self-maintaining an instrumental activities of daily living. Gerontologist 9: 179–186

    Article  PubMed  CAS  Google Scholar 

  • Lehmann E (1984) Practicabel and valid approach to evaluate the efficacy of nootropic drugs by means of rating scales. Pharmacopsychiatry 17: 71–75

    Article  PubMed  CAS  Google Scholar 

  • Levine RL (1986) Ethics and regulation of clinical research. Urban & Schwarzenberg, Baltimore München

    Google Scholar 

  • Lynch G, Larson J, Staubli U, Baudry M (1987) New perspectives on the physiology, chemistry and pharmacology of memory. Drug Dev Res 10: 295–315

    Article  CAS  Google Scholar 

  • Markstein R (1989) Pharmacological approaches in the treatment of senile dementia. Eur Neurol 28: 136–144

    Google Scholar 

  • Matthies H (1985) Zentralnervensystem. In: Markwardt F, Matthies H, Oelssner W (Hrsg) Medizinische Pharmakologie. VEB Georg Thieme, Leipzig

    Google Scholar 

  • Maurer K, Riederer P, Beckmann H (eds) (1990) Alzheimer’s disease. Epidemiology, neuropathology, neurochemistry and clinics. Springer, Wien New York (Key topics in brain research)

    Google Scholar 

  • Merlini L, Pinza M (1989) Trends in searching for new cognition enhancing drugs. Prog NeuroPsychopharmacol Biol Psychiatry 13: 61–75

    Article  Google Scholar 

  • Mohs RC, Rosen WG, Davis KL (1983) The Alzheimer’s disease asssessment scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull 19: 448–449

    PubMed  CAS  Google Scholar 

  • Moos WH, Davis E, Schwarz RD, Gamzu ER (1988) Cognition activators. Med Res Rev 8: 353–391

    Article  PubMed  CAS  Google Scholar 

  • Oswald WD, Fleischmann UM (1986) Das Nürnberger-Alters-Inventar NAI. Hogrefe, Göttingen

    Google Scholar 

  • Oswald WD, Roth E (1987) Der Zahlen-Verbindungs-Test, 2. Aufl. Hogrefe, Göttingen

    Google Scholar 

  • Oswald WD, Fleischmann UM (1989) Psychometric assessment in psychogeriatrics. In: Bergener M et al. (eds) Psychogeriatrics — A new paradigm on basic research and clinical practice. Springer, New York

    Google Scholar 

  • Pfeiffer E (1975) Short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J Am Geriatr Soc 23: 433–441

    PubMed  CAS  Google Scholar 

  • Reisberg B, Ferris SH, DE Leon MJ, Crook T (1982) The global deterioration scale (GDS). An instrument for the assessment of primary degenerative dementia (PDD). Am J Psychiatry 139: 1136–1139

    PubMed  CAS  Google Scholar 

  • Reisberg B, Schneck MK, Ferris SH, Schwarz GE, DE Leon MJ (1983) The brief cognitive rating scale (BCRS). Psychopharmacol Bull 19: 47–50

    Google Scholar 

  • Reitan RM (1985) Validity of the trail making test as an indicator of organic brain damage. Perceptual and Motor Skills 8: 271–276

    Google Scholar 

  • Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer’s disease. Am J Psychiatry 141: 1356–1364

    PubMed  CAS  Google Scholar 

  • Rom M, Tym E, Mountjoy CQ, Huppert FA, Hendrie H, Verma S, Goddard R (1986) Camdex — A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 149: 698–709

    Article  Google Scholar 

  • Schindler U (1989) Pre-clinical evaluation of cognition enhancing drugs. Prog Neuro-Psychopharmacol Biol Psychiatry 13: 99–115

    Article  Google Scholar 

  • Schmidt J (1984) Zur Pharmakologie der Nootropika. Beiträge zur Wirkstofforschung Heft 17. Akademie-Industrie-Komplex-Arzneimittelforschung, Berlin

    Google Scholar 

  • Schneider HD, Fisch HP (1981) Der geriatrische Beurteilungsbogen (GBB): Ein Instrument zur Einschätzung des Alltagsverhaltens geriatrischer Patienten durch das Pflegepersonal. In: Oswald WD, Fleischmann UM (Hrsg) Experimentelle Gerontopsychologie. Beltz, Weinheim, S 116–130

    Google Scholar 

  • Schwartz GE (1983) Development and validation of the geriatic evaluation by the relative’s rating instrument (GERRJ). Psychol Reports 53: 479–488

    Article  CAS  Google Scholar 

  • Shader RI, Harmatz JS, Salzman C (1974) A new scale for clinical assessment in geriatric populations: Sandoz clinical assessment geriatric scale (SCAG). J Am Geriatr Soc 22: 107–113

    PubMed  CAS  Google Scholar 

  • Skondia V (1979) Criteria for clinical development and classification of nootropic drugs. Clin Ther 2/5: 316–332

    Google Scholar 

  • Thomae H (1984) Lebenszufriedenheit. In: Oswald WD, Hermann WM, Kanowski S, LEHR UM, Thomae H (Hrsg) Gerontologie. Kohlhammer, Stuttgart, S 271–275

    Google Scholar 

  • Wechsler D (1964) Die Messung der Intelligenz Erwachsener. Hogrefe, Göttingen

    Google Scholar 

  • Wenk GL, Olton DS (1989) Cognitive enhancers: potential strategies and experimental results. Prog Neuro-Psychopharmacol Biol Psychiatry 13: 117–139

    Article  Google Scholar 

  • Wood WG, Strong R (eds) (1987) Geriatric clinical pharmacology. Raven Press, New York

    Google Scholar 

  • Wurtman RJ, Corkin S, Growdon HJ (eds) (1987) Topics in the basic and clinical science of dementia. J Neural Transm [Suppl 24]: 1–329

    Google Scholar 

  • Who (1989) Draft of the intemational classification of disease, 10th revision (ICD 10). Genova

    Google Scholar 

  • Zaudig M, Mittelhammer J, Hiller W, Pauls A, Thora C, Morinigo A, Mombour W (1991) SIDAM-A structured interview for the diagnosis of dementia of the Alzheimer type, multiinfarct dementia and dementias of other aetiology according to ICD 10 and DSM III-R. Psychol Med 21: 225–236

    Article  PubMed  CAS  Google Scholar 

  • Zimmer R, Kurz A, Lauter H (1987) Zur klinischen Relevanz nootroper Effekte. In: Cooper H, Heimann H, Kanowski S, Kunkel H (Hrsg) Hirnorganische Psychosyndrome im Alter III. Springer, Berlin Heidelberg New York Tokyo, S 54–61

    Chapter  Google Scholar 

  • Alhainen K, Riekkinen PJ, Helkala EL, Partanen Laulumaa V, Reinikainen K, Soininen H, Airaksinen M (1991) The effects of THA on cognitive functions and spectral power EEG in Alzheimer’s disease: preliminary results of an open study. In: IQBAL K, Mclachlan DRC, Winblad B, Wisniewski HM (eds) Alzheimer’s disease: basis mechanism, diagnosis and therapeutic strategies. Wiley, Chichester New York, pp 611–619

    Google Scholar 

  • Amaducci L, Angst J, Bech P, Benkert O, Bruinvels J, Engel RR, Gottfries CG, Hippius H, Levy R (1990) Consensus conference on the methodology of clinical trials of “Nootropics”. Pharmacopsychiatry 23: 171–175

    Article  PubMed  CAS  Google Scholar 

  • American Electroencephalographic Society (1987) Statement on the clinical use of quantitative EEG. J Clin Neurophysiol 4: 197

    Article  Google Scholar 

  • Coper H, Herrmann WM (1988) Psychostimulants, analeptics, nootropics: an attempt to differentiate and assess drugs designed for the treatment of impaired brain functions. Pharmacopsychiatry 21: 211–217

    Article  PubMed  CAS  Google Scholar 

  • Dierks T, Maurer K (1990) Reference-free evaluation of auditory evoked potentials P300 in aging and dementia. In: Dostert P, Riederer P, Strolin Benedetti M, Roncucci R (eds) Early markers in Parkinson’s and Alzheimer’s disease. Springer, Wien New York, pp 197–208 (New Vistas in Drug Research)

    Chapter  Google Scholar 

  • Dierks T, Perisic I, Froelich L, IHL R, Maurer K (1991) Topography of quantitative EEG in dementia of Alzheimer type: relation to severity of dementia. Psychiatry Res 40: 181–194

    Article  PubMed  CAS  Google Scholar 

  • Dietrich B, Herrmann WM, Coppola R (1989) Untersuchungen zur Wirkung von Phosphatidylserine-Fidia auf eine funktionale zerebrale Ebene mit Hilfe der EEG-Mapping-Technik. In: Saletu B (Hrsg) Biologische Psychiatrie. Thieme, Stuttgart New York, S 238–240

    Google Scholar 

  • Duffy FH, Burchfiel JL, Lombroso CT (1979) Brain electrical activity mapping (BEAM): a method for extending the clinical utility of EEG and evoked potential data. Ann Neurol 5: 309–321

    Article  PubMed  CAS  Google Scholar 

  • Duffy FH, Albert MS, Mcanulty G (1984) Brain electrical activity in patients with presenile and senile dementia of the Alzheimer type. Ann Neurol 16: 439–448

    Article  PubMed  CAS  Google Scholar 

  • Dummermuth G, Ferber G, Herrmann WM, Hinrichs H, Kuenkel H (1987) Recommendations for standardization of data acquisition and signal analysis in pharmaco-electroencephalography. Neuropsychobiology 17: 213–218

    Article  Google Scholar 

  • Fink M (1969) EEG and human psychopharmacology. A Rev Pharmacol 9: 241–258

    Article  CAS  Google Scholar 

  • Fink M (1975) Central electrometry-quantitative EEG applied to human psychopharmacology. In: Dolce G, Kunkel H (eds) CEAN-computerized EEG-analysis. Fischer, Stuttgart

    Google Scholar 

  • Fritze J, Dierks T, Maurer K (1989) EEG mapping during cholinergic drug challenge with RS-86. In: Maurer K (ed) Topographic brain mapping of EEG and evoked potentials. Springer, Berlin Heidelberg New York Tokyo, pp 518–521

    Chapter  Google Scholar 

  • Fünfgeld EW (1989) A natural and broad spectmm nootropic substance for treatment of SDAT — the ginkgo biloba extract. Prog Clin Biol Res 317: 1247–1260

    PubMed  Google Scholar 

  • Grossmann WM, Standl A, May U, Van Laak HH, Hirche H (1990) Naftidrofuryl in the treatment of mild senile dementia. Pharmacopsychiatry 23: 265–273

    Article  PubMed  CAS  Google Scholar 

  • Herrmann WM (1982a) Development and critical evaluation of an objective procedure for the electroencephalographic classification of psychotropic drugs. In: Herrmann WM (ed) Electroencephalography in drug research. Fischer, Stuttgart, pp 249–351

    Google Scholar 

  • Herrmann WM (1982b) Electroencephalography and drug research. Fischer, Stuttgart

    Google Scholar 

  • Herrmann WM, Scharer E (1988) Wirkungen und Wirksamkeit von Nootropika. In: Helmchen H (Hrsg) Wirkungen und Wirksamkeit von Nootropika. Springer, Berlin Heidelberg New York Tokyo, S 71–93

    Chapter  Google Scholar 

  • Herrmann WM, Kern U, Roehmel J (1986) Contribution to the search of vigilance indicative EEG variables: results of a controlled, doubleblind study with pyritinol in elderly patients with symptoms of mental dysfunction. Pharmacopsychiatry 19: 75–83

    Article  PubMed  CAS  Google Scholar 

  • Herrmann WM, Coppola R, Etevenon P, Ferber G, Fink M, Gevins AS, Hinrichs H, Itil TM, John ER, Kubicki ST, Kuenkel H, Kugler J, Lehmann D, Petsche H, Rappelsberger P, Roehmel J, Saito M, Saletu B, Scheuler W (1989a) International Pharmaco-EEG Group (IPEG). Recommendations for EEG and evoked potential mapping. Neuropsychobiology 22: 170–176

    Article  Google Scholar 

  • Herrmann WM, Kubicki ST, Kuenkel H, Kugler J, Lehmann D, Maurer K, Rappelsberger P, Scheuler W (1989b) Empfehlungen der Deutschen EEG-Gesellschaft für das Mapping von EEG-Parametern (EEG- und EP- Mapping). EEG-EMG 20: 125–132

    PubMed  CAS  Google Scholar 

  • Ihl R, Dierks T, Maurer K (1989a) Demenz vom vaskulärem Typ — Effekte einer Infusionstherapie mit Xantinolnicotinat. In: Saletu B (Hrsg) Biologische Psychiatrie. Thieme, Stuttgart New York, S 232–234

    Google Scholar 

  • Ihl R, Frölich L, Dierks T, Maurer K (1989b) Influence of physostigmine on cognitive processing of the brain. In: Basar E et al. (eds) Springer Series in Brain Dynamics 2. Springer, Berlin Heidelberg New York Tokyo, pp 429–435

    Chapter  Google Scholar 

  • Ihl R, Maurer K, Dierks T, Wannenmacher W (1989c) EEG and EP mapping in patients with senile dementia of Alzheimer type before and after treatment with pyritinol. In: Maurer K (ed) Topographic brain mapping of EEG and evoked potentials. Springer, Berlin Heidelberg New York Tokyo, pp 241–248

    Chapter  Google Scholar 

  • Itil TM (1974) Quantitative pharmaco-electroencephalography. Use of computerized cerebral biopotentials in psychotropic drug research. In: ITIL TM (ed) Psychotropic drugs and the human EEG. Karger, Basel, pp 43–75

    Google Scholar 

  • Itil TM, Menon GN, Songar A, Itil KZ (1986) CNS pharmacology and clinical therapeutic effects of oxiracetam. Clin Neuropharmacol 9 [Suppl 3]: S70–S72

    PubMed  Google Scholar 

  • Kraaier V, Van Huffelen AC, Wieneke GH (1989) The hyperventilation-induced ischaemia model in human neuropharmacology: neurophysiological and psychometric studies of aniracetam and 3-OH aniracetam. Eur J Clin Pharmacol 36: 605–611

    Article  PubMed  CAS  Google Scholar 

  • Krassner MB (1984) Mechanism of action of hydergin (ergoloid mesylates) in relation to organic brain disorders. Adv Ther 1: 172–188

    Google Scholar 

  • Lehmann D (1971) Multichannel topography of human alpha EEG fields. Electroencephalogr Clin Neurophysiol 31: 439–449

    Article  PubMed  CAS  Google Scholar 

  • Leponcin-Lafitte M (1985) Learning and cholinergic neurotransmission in old animals: the effect of hydergine. J Pharmacol 16: 57–63

    Google Scholar 

  • Maurer K, Dierks T (1991) Atlas of brain mapping. Springer, Berlin Heidelberg New York Tokyo

    Book  Google Scholar 

  • Maurer K, Dierks T, Ihl R (1989a) The effect of pyritinol upon P300 topography. Psychiatry Res 29: 413–415

    Article  PubMed  CAS  Google Scholar 

  • Maurer K, Riederer P, Heinsen H, Beckmann H (1989b) Altered P300 topography due to functional and structural disturbances in the limbic system in dementia and psychoses and to psychopharmacological conditions. Psychiatry Res 29: 391–394

    Article  PubMed  CAS  Google Scholar 

  • Maurer K, Dierks T, Strik WK, Frölich L (1990) P3 topography in psychiatry and psychopharmacology. Brain Topogr 3: 79–84

    Article  PubMed  CAS  Google Scholar 

  • Münte TT, Heinze HJ, Scholz MB, Bartusch SM, Dietrich De (1989) Event-related potentials and visual spatial attention: influence of a cholinergic drug. Neuropsychobiology 21: 94–99

    Article  PubMed  Google Scholar 

  • Pfefferbaum A, Wenegrat BG, Ford JM, Roth WT, Kopell BS (1984) Clinical application of the P3 component of event-related potentials. II. Dementia, depression and schizophrenia. Electroencephalogr Clin Neurophysiol 59: 104–124

    Article  PubMed  CAS  Google Scholar 

  • Rupprecht R, Maurer K, Dierks T, Ihl R (1989) Topographic mapping of pharmaco-EEG before and after application of phosphatidylserine. Psychiatry Res 29: 417–418

    Article  PubMed  CAS  Google Scholar 

  • Saletu B, Linzmayer L, Grünberger J, Pietschmann H (1985) Double-blind, placebo-controlled, clinical, psychometric and neurophysiological investigations with oxiracetam in the organic brain syndrome of late life. Neuropsychobiology 13: 44–52

    Article  PubMed  CAS  Google Scholar 

  • Saletu B, Anderer P, Kinsberger K, Grünberger J (1987) Topographic brain mapping of EEG in neuropsychopharmacology. Part II. Clinical applications (pharmaco EEG imaging). Meth Find Exp Clin Pharmacol 9: 385–408

    CAS  Google Scholar 

  • Saletu B, Anderer P, Paulus E, Grünberger J, Wicke L, Neuhold A, Fischhof PK, Litschauer G, Wagner G, Hatzinger R, Dittrich R (1988) EEG brain mapping in SDAT and MID patients before and during placebo and xantinolnicotinate therapy: reference considerations. In: Samsondolfuss (ed) Statistics and topography in quantitative EEG. Elsevier, Paris, pp 251–275

    Google Scholar 

  • Saletu B, Anderer P, Kinsberger K, Grünberger J (1989a) Topographic EEG brain maps and mental performance under hypoxia after placebo and pyritinol. In: Maurer K (ed) Topographic brain mapping of EEG and evoked potentials. Springer, Berlin Heidelberg New York, pp 527–534

    Chapter  Google Scholar 

  • Saletu B, Darragh A, Salmon P, Coen R (1989b) EEG brain mapping in evaluating the timecourse of the central action of DUP 996 — a new acetylcholine releasing drug. Br J Clin Pharmacol 28: 1–16

    Article  PubMed  CAS  Google Scholar 

  • Saletu B, Semlitsch HV, Anderer P, Resch F, Presslich O, Schuster P (1989c) Psychophysiological research in psychiatry and neuropsychopharmacology. II. The investigation of antihypoxidotic/nootropic drugs (tenilsetam and co-dergocrine-mesylate) in elderlies with the Viennese psychophysiological test-system (VPTS). Meth Find Exp Clin Pharmacol 11: 43–55

    CAS  Google Scholar 

  • Saletu B, Anderer P, Grünberger J (1990a) Topographic mapping of EEG after acute application of ergotalkaloids in the elderly. Arch Gerontol Geriatr 11: 1–22

    Article  PubMed  CAS  Google Scholar 

  • Saletu B, Grünberger J, Anderer P (1990b) On brain protection of co-dergocrine mesylate (Hydergine) against hypoxic hypoxidosis of different severity: double-blind placebo-controlled quantitative EEG and psychometric studies. Int J Clin Pharmacol Ther Toxicol 28: 510–524

    PubMed  CAS  Google Scholar 

  • Saletu B, Grünberger J, Linzmayer L, Anderer P (1990c) Brain protection of nicergoline against hypoxia: EEG brain mapping and psychometry. J Neural Transm [PD-Sect] 2: 305–325

    Article  CAS  Google Scholar 

Download references

Authors
  1. H. Herrschaft
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Dierks
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Ihl
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. Maurer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Psychiatrische Universitätsklinik, Würzburg, Bundesrepublik Deutschland

    Peter Riederer

  2. Psychiatrische Universitätsklinik, Bonn, Bundesrepublik Deutschland

    Gerd Laux

  3. Psychiatrische Universitätsklinik, Basel, Schweiz

    Walter Pöldinger

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer-Verlag Wien

About this chapter

Cite this chapter

Herrschaft, H., Dierks, T., Ihl, R., Maurer, K. (1992). Klinische Bewertung der Wirksamkeit von Nootropika. In: Riederer, P., Laux, G., Pöldinger, W. (eds) Neuro-Psychopharmaka. Springer, Vienna. https://doi.org/10.1007/978-3-7091-3330-9_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-3330-9_11

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-3331-6

  • Online ISBN: 978-3-7091-3330-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation